PALO ALTO, CA — March 11, 2026
BridgeBio Pharma announced that its investigational therapy BBP-418 demonstrated consistent efficacy and a favorable safety profile in the Phase 3 FORTIFY interim analysis for patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), a rare genetic neuromuscular disorder. The findings highlight the potential of BBP-418 as a disease-modifying oral therapy, addressing a significant unmet need for individuals living with this progressive muscle disease. Interim results from the pivotal FORTIFY clinical trial showed meaningful improvements across functional, biomarker, and respiratory measures, reinforcing confidence in the therapy’s potential to transform treatment outcomes for patients with FKRP-related muscular dystrophy.
Phase 3 FORTIFY Trial Demonstrates Significant Clinical Benefits
The FORTIFY study is a randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy and safety of BBP-418 in individuals diagnosed with LGMD2I/R9, a rare inherited disease caused by mutations affecting muscle cell stability. The trial enrolled patients across multiple international sites and aims to assess improvements in motor performance, respiratory function, and molecular biomarkers associated with disease progression.
Results from the interim analysis revealed that BBP-418 successfully met all primary and secondary efficacy endpoints, demonstrating statistically significant improvements in clinical and molecular outcomes compared with placebo. Patients receiving the therapy showed improvements in muscle strength, walking ability, and pulmonary function, key indicators of disease progression in muscular dystrophy.
Researchers noted that the therapy demonstrated clinically meaningful benefits across multiple disease measures, suggesting that BBP-418 may help stabilize or improve muscle function in individuals living with LGMD2I/R9.
Advertisement
Favorable Safety Profile Supports Continued Development
In addition to demonstrating strong efficacy signals, the interim analysis confirmed that BBP-418 maintains a favorable safety and tolerability profile, consistent with findings observed in earlier clinical studies. The therapy was well tolerated by participants, with no unexpected safety concerns reported during the trial.
Safety data from the study further reinforce the potential of BBP-418 as a long-term treatment option for patients with rare neuromuscular disorders, where maintaining a positive risk-benefit profile is essential for regulatory approval and widespread clinical adoption.
LGMD2I/R9 is characterized by progressive muscle weakness affecting the hips, shoulders, and respiratory muscles, often leading to mobility limitations and reduced quality of life. Currently, no disease-modifying therapies are approved specifically for this genetic form of muscular dystrophy, highlighting the urgent need for innovative treatments.
By addressing the underlying molecular defect associated with the disease, BBP-418 aims to restore glycosylation of αDG, a key protein responsible for maintaining muscle cell stability and function. This targeted mechanism of action represents a promising therapeutic strategy for rare genetic muscle disorders.
Regulatory Plans and Future Development Pathway
Based on the positive interim results from the Phase 3 FORTIFY trial, BridgeBio plans to move forward with regulatory discussions and submission plans aimed at bringing BBP-418 to patients as quickly as possible. The company has indicated that it intends to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the first half of 2026, marking a major milestone in the therapy’s development pathway.
If approved, BBP-418 could become the first disease-modifying oral therapy for LGMD2I/R9, providing new hope for patients living with this rare and debilitating condition. The therapy’s potential to improve muscle function, respiratory performance, and biomarker profiles underscores its importance within the evolving landscape of genetic disease treatments.
BridgeBio continues to advance a broad pipeline focused on genetically driven diseases, using targeted molecular approaches to address conditions with limited or no therapeutic options. The progress of BBP-418 in the Phase 3 FORTIFY trial represents a significant milestone in the company’s mission to develop transformative therapies for rare diseases.
As additional clinical data become available, researchers and clinicians will continue evaluating the therapy’s long-term impact on disease progression, functional outcomes, and patient quality of life, potentially shaping the future treatment landscape for limb-girdle muscular dystrophy and related neuromuscular disorders.
z
Source: BridgeBio Pharma press release
